Showing 17,641 - 17,660 results of 107,763 for search '(( 5 ((mean decrease) OR (a decrease)) ) OR ( e ((non decrease) OR (point decrease)) ))', query time: 1.12s Refine Results
  1. 17641
  2. 17642
  3. 17643
  4. 17644
  5. 17645

    Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Stud... by Ken Ohta (727449)

    Published 2015
    “…Commonly reported AEs with tiotropium 5 μg, 2.5 μg and placebo were nasopharyngitis (48.2%, 44.7%, 42.1%), asthma (28.9%, 29.8%, 38.6%), decreased PEFR (15.8%, 7.9%, 21.1%), bronchitis (9.6%, 13.2%, 7.0%), pharyngitis (7.9%, 13.2%, 3.5%) and gastroenteritis (10.5%, 3.5%, 5.3%). …”
  6. 17646
  7. 17647
  8. 17648
  9. 17649
  10. 17650

    Risk of bias across 22 included studie. by Kuo-Chuan Hung (8587392)

    Published 2024
    “…Trial sequential analysis (TSA) was conducted to validate the reliability.</p><p>Results</p><p>A meta-analysis of 22 RCTs (n = 3,463) showed that ketamine/esketamine significantly decreased PPD risk at 1- (risk ratio [RR], 0.41; 95% confidence interval [CI], 0.3–0.57) and 4–6-week (RR, 0.47; 95%CI, 0.35–0.63) follow-ups. …”
  11. 17651

    An overview of the selection process for studies. by Kuo-Chuan Hung (8587392)

    Published 2024
    “…Trial sequential analysis (TSA) was conducted to validate the reliability.</p><p>Results</p><p>A meta-analysis of 22 RCTs (n = 3,463) showed that ketamine/esketamine significantly decreased PPD risk at 1- (risk ratio [RR], 0.41; 95% confidence interval [CI], 0.3–0.57) and 4–6-week (RR, 0.47; 95%CI, 0.35–0.63) follow-ups. …”
  12. 17652

    Characteristics of studies (<i>n</i> = 22). by Kuo-Chuan Hung (8587392)

    Published 2024
    “…Trial sequential analysis (TSA) was conducted to validate the reliability.</p><p>Results</p><p>A meta-analysis of 22 RCTs (n = 3,463) showed that ketamine/esketamine significantly decreased PPD risk at 1- (risk ratio [RR], 0.41; 95% confidence interval [CI], 0.3–0.57) and 4–6-week (RR, 0.47; 95%CI, 0.35–0.63) follow-ups. …”
  13. 17653
  14. 17654
  15. 17655
  16. 17656

    Nt5e is a trypsin-cleavable surface protein of <i>S. sanguinis</i> and affects platelet aggregation lag time. by Jingyuan Fan (159998)

    Published 2012
    “…All samples contained 15 µg of protein solubilized in 1% (w/v) SDS sample buffer. These samples were electrophoresed on a 10% gel, and stained with Coomassie Blue. …”
  17. 17657

    Integrin αVβ5 antibody inhibits the uptake of ROS by piPSC-RPE cells. by Jie Gong (339362)

    Published 2015
    “…Addition of an inhibitory anti-integrin αVβ5 antibody significantly decreased phagocytosis by approximately 50% in piPSC-RPE cells. …”
  18. 17658
  19. 17659

    A Systematic Review of Surface Contamination, Stability, and Disinfection Data on SARS-CoV‑2 (Through July 10, 2020) by Noah Bedrosian (9675117)

    Published 2020
    “…We conducted a systematic review of hygiene intervention effectiveness against SARS-CoV-2, including developing inclusion criteria, conducting the search, selecting articles for inclusion, and summarizing included articles. …”
  20. 17660

    A Systematic Review of Surface Contamination, Stability, and Disinfection Data on SARS-CoV‑2 (Through July 10, 2020) by Noah Bedrosian (9675117)

    Published 2020
    “…We conducted a systematic review of hygiene intervention effectiveness against SARS-CoV-2, including developing inclusion criteria, conducting the search, selecting articles for inclusion, and summarizing included articles. …”